• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4597351)   Today's Articles (5551)   Subscriber (49349)
Number Citation Analysis
251
Russell MR, Penikis A, Oldridge DA, Alvarez-Dominguez JR, McDaniel L, Diamond M, Padovan O, Raman P, Li Y, Wei JS, Zhang S, Gnanchandran J, Seeger R, Asgharzadeh S, Khan J, Diskin SJ, Maris JM, Cole KA. CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Res 2015;75:3155-66. [PMID: 26100672 DOI: 10.1158/0008-5472.can-14-3613] [Citation(s) in RCA: 109] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Accepted: 05/05/2015] [Indexed: 12/15/2022]
252
Kolb EA, Gorlick R, Keir ST, Maris JM, Kang MH, Reynolds CP, Lock RB, Carol H, Wu J, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 2015;62:1106-9. [PMID: 25407467 PMCID: PMC4405429 DOI: 10.1002/pbc.25329] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2014] [Accepted: 09/26/2014] [Indexed: 11/06/2022]
253
Shusterman S, London WB, Hank JA, Parisi MT, Shulkin BL, Servaes SEN, Naranjo A, Shimada H, Gan J, Gillies S, Maris JM, Park JR, Sondel PM. A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children’s Oncology Group study. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.10017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
254
Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. 131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. Biol Blood Marrow Transplant 2015;21:673-81. [DOI: 10.1016/j.bbmt.2014.12.008] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2014] [Accepted: 12/09/2014] [Indexed: 12/26/2022]
255
Smith MA, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Carol H, Lock RB, Keir ST, Maris JM, Billups CA, Lyalin D, Kurmasheva RT, Houghton PJ. Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program. Clin Cancer Res 2015;21:819-32. [PMID: 25500058 PMCID: PMC4587665 DOI: 10.1158/1078-0432.ccr-14-2572] [Citation(s) in RCA: 92] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
256
Maris JM, Knudson AG. Revisiting tissue specificity of germline cancer predisposing mutations. Nat Rev Cancer 2015;15:65-6. [PMID: 25688405 DOI: 10.1038/nrc3894] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
257
Smith MA, Hampton OA, Reynolds CP, Kang MH, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Kurmasheva RT, Wheeler DA, Houghton PJ. Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatr Blood Cancer 2015;62:91-8. [PMID: 25263539 PMCID: PMC4456187 DOI: 10.1002/pbc.25201] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Accepted: 07/07/2014] [Indexed: 12/31/2022]
258
Attiyeh EF, Maris JM. Identifying rare events in rare diseases. Clin Cancer Res 2014;21:1782-5. [PMID: 25424848 DOI: 10.1158/1078-0432.ccr-14-2314] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2014] [Accepted: 10/23/2014] [Indexed: 11/16/2022]
259
Bosse KR, Diskin SJ, Cole K, Mayes P, Winter C, Diamond M, Laudenslager M, Attiyeh EF, Norris G, Mosse YP, Capasso M, Devoto M, Rappaport ER, Irminger I, Maris JM. Abstract 3867: Understanding the neuroblastoma predisposition signal at chromosome 2q35: Identification of the β-BARD1 isoform as an oncogenic driver. Epidemiology 2014. [DOI: 10.1158/1538-7445.am10-3867] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
260
Houghton PJ, Kurmasheva RT, Lyalin D, Maris JM, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Smith MA. Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatr Blood Cancer 2014;61:1972-9. [PMID: 25131802 PMCID: PMC4201390 DOI: 10.1002/pbc.25175] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2014] [Accepted: 06/16/2014] [Indexed: 01/19/2023]
261
Attiyeh EF, McKeon-Fish A, Trillo R, Landesman Y, Senapedis W, McCauley D, Kashyap T, Shacham S, Kauffman M, Maris JM. Abstract B36: Inhibition of Exportin 1 (XPO1) potently suppresses growth of human neuroblastoma cell lines. Cancer Res 2014. [DOI: 10.1158/1538-7445.pedcan-b36] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
262
Hart LS, Batra V, Raman P, Gagliardi M, Rader J, Chen L, Fritsch C, Caponigro G, Peters M, Boehm M, Maris JM. Abstract B82: MEK 1/2 inhibition and biomarkers of response in preclinical models of neuroblastoma. Cancer Res 2014. [DOI: 10.1158/1538-7445.pedcan-b82] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
263
Wei JS, Patidar R, Shern J, Zhang S, Pugh T, Diskin SJ, Sindiri S, Song YK, Liao H, Wen X, Wang J, Skapek SX, Anderson JR, Barr FG, Seeger RC, Maris JM, Hawkins D, Khan J. Abstract A12: Systematic identification of germline mutations in rhabdomyosarcoma and neuroblastoma using massively paralleled sequencing. Cancer Res 2014. [DOI: 10.1158/1538-7445.pedcan-a12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
264
Wang LL, Teshiba R, He L, Naranjo A, London WB, Gastier-Foster JM, Seeger RC, Cohn SL, Maris JM, Park JR, Hogarty MD, Shimada H. Abstract B40: MYCN/MYC protein expression in high-MKI (Mitosis-Karyorrhexis Index) neuroblastomas: A report from the Children's Oncology Group. Cancer Res 2014. [DOI: 10.1158/1538-7445.pedcan-b40] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
265
Ali SM, Hawryluk MJ, Wang K, Chmielecki J, Palmer GA, Garcia L, White E, Yelensky R, Stephens PJ, Ross JS, Maris JM, Miller VA. Abstract A28: Clinical next-generation sequencing (NGS) reveals genomic alterations (GAs) to guide targeted therapy in advanced neuroblastoma patients. Cancer Res 2014. [DOI: 10.1158/1538-7445.pedcan-a28] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
266
Oldridge DA, Wood A, Winter C, Diamond M, Crimmins I, Zhang S, Wei J, Khan J, Capasso M, Rahman N, Diskin SJ, Maris JM. Abstract A27: A noncoding polymorphism in a GATA-containing enhancer element drives the association of LMO1 with neuroblastoma. Cancer Res 2014. [DOI: 10.1158/1538-7445.pedcan-a27] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
267
Capasso M, Diskin S, Cimmino F, Acierno G, Totaro F, Petrosino G, Pezone L, Diamond M, McDaniel L, Hakonarson H, Iolascon A, Devoto M, Maris JM. Common genetic variants in NEFL influence gene expression and neuroblastoma risk. Cancer Res 2014;74:6913-24. [PMID: 25312269 DOI: 10.1158/0008-5472.can-14-0431] [Citation(s) in RCA: 73] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
268
Wei JS, Patidar R, Shern J, Zhang S, Pugh T, Diskin SJ, Sindiri S, Song YK, Liao H, Wen X, Wang J, Skapek SX, Anderson JR, Barr FG, Seeger RC, Maris JM, Hawkins DS, Khan J. Abstract 5081: Systematic identification of germline mutations in rhabdomyosarcoma and neuroblastoma using massively paralleled sequencing. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-5081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
269
Altman BJ, Hsieh A, Gouw AM, Stine ZE, Venkataraman A, Bellovin DI, Diskin SJ, Lu W, Zhang S, Felsher DW, Maris JM, Lazar MA, Rabinowitz JD, Hogenesch JB, Dang CV. Abstract 2953: Rev-erbα modulates Myc-driven cancer cell growth and altered metabolism. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-2953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
270
McDaniel LD, Maris JM. The promises and pitfalls of genetic epidemiologic approaches to pediatric cancers: lessons from MDM2. Pediatr Blood Cancer 2014;61:1717-8. [PMID: 24938213 DOI: 10.1002/pbc.25051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2014] [Accepted: 03/10/2014] [Indexed: 11/05/2022]
271
Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Lyalin D. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer 2014;61:1493-6. [PMID: 24664981 PMCID: PMC4225044 DOI: 10.1002/pbc.25026] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2014] [Accepted: 02/17/2014] [Indexed: 02/06/2023]
272
Kang MH, Reynolds CP, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Wu J, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer 2014;61:1486-9. [PMID: 24623675 PMCID: PMC4248662 DOI: 10.1002/pbc.24989] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/18/2013] [Accepted: 01/21/2014] [Indexed: 12/12/2022]
273
Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, London WB, Maris JM, Balis FM. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). Pediatr Blood Cancer 2014;61:990-6. [PMID: 24347462 PMCID: PMC5127168 DOI: 10.1002/pbc.24900] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/11/2013] [Accepted: 11/19/2013] [Indexed: 11/11/2022]
274
Ozkaynak MF, Gilman AL, Yu AL, London WB, Sondel PM, Smith MA, Seeger R, Reynolds CP, Maris JM, Park JR. A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.10044] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
275
Twist C, London WB, Naranjo A, Schmidt ML, Adkins ES, Mattei P, Cretella S, Cohn SL, Park JR, Maris JM. Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: A report from the Children’s Oncology Group study ANBL0531. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.10006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
PrevPage 11 of 21 121011122021Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA